Healthcare Finance News April 3, 2024
Total gross Medicare spending on GLP-1 drugs has skyrocketed, rising from $57 million in 2018 to $5.7 billion in 2022.
Spending on GLP-1 drugs under the Medicare Part D program has increased dramatically in recent years, and the annual cost of these drugs in the United States – upwards of $11,000 at recent list prices – has raised concerns about the fiscal impact of broad coverage of GLP-1 drugs on Medicare, other health insurers and patients, a KFF analysis finds.
GLP-1 drugs such as Ozempic, Wegovy and Mounjaro were initially developed to treat type 2 diabetes, but have demonstrated effectiveness in treating obesity and their popularity has grown as a result. These drugs are also being tested to treat other...
Today's Sponsors
Today's Sponsor